Clinical Trial: A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia

U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07416032) titled 'A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia' on Feb. 10.

Brief Summary: This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells(QT-019C) in Patients With Refractory Primary Immune Thrombocytopenia.

Study Start Date: Feb. 20

Study Type: INTERVENTIONAL

Condition: Immune Thrombocytopenia (ITP)

Intervention: DRUG: QT-019C

QT-019C is a chimeric antigen receptor T-cell (CAR-T) therapy targeting both BCMA and C...